D. Yee

D. Yee, J. Jackson, Douglas Yee, 1999, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Neoadjuvant as Future for Drug Development in Breast Cancer—Response

D. Berry, L. Esserman, D. Yee, 2016, Clinical Cancer Research.

The insulin-like growth factors and breast cancer — revisited

D. Yee, 1998, Breast Cancer Research and Treatment.

Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL

D. Berry, N. Hylton, O. Olopade, 2013 .

Safety and Efficacy of Weight Training in Recent Breast Cancer Survivors to Alter Body Composition, Insulin, and Insulin-Like Growth Factor Axis Proteins

D. Yee, K. Schmitz, P. Hannan, 2005, Cancer Epidemiology, Biomarkers and Prevention.

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update

G. Hortobagyi, L. Carey, D. Yee, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Dual-Radioisotope Hybrid Whole-Body Micro-Positron Emission Tomography/Computed Tomography System Reveals Functional Heterogeneity and Early Local and Systemic Changes Following Targeted Radiation to the Murine Caudal Skeleton

D. Yee, M. Koizumi, K. Ogawa, 2014, Calcified Tissue International.

Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens

D. Yee, M. Kirstein, W. Elmquist, 2006, Breast Cancer Research and Treatment.

Advances in insulin-like growth factor biology and -directed cancer therapeutics.

D. Yee, Lynsey M. Fettig, L. M. Fettig, 2020, Advances in cancer research.

FKHR binds the insulin response element in the insulin-like growth factor binding protein-1 promoter.

D. Yee, J. Jackson, D. Powell, 1999, Endocrinology.

Feasibility of single‐voxel MRS measurement of apparent diffusion coefficient of water in breast tumors

D. Yee, M. Nelson, M. Garwood, 2009, Magnetic resonance in medicine.

Use of 18F-FDG PET/CT as an Initial Staging Procedure for Stage II-III Breast Cancer: A Multicenter Value Analysis.

L. Esserman, D. Yee, C. Yau, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds

D. Yee, B. Hackel, J. Chan, 2017, Molecular Cancer Therapeutics.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors

L. Esserman, D. Yee, B. Hann, 2017, Breast Cancer Research.

Sequencing of Type I Insulin-Like Growth Factor Receptor Inhibition Affects Chemotherapy Response In vitro and In vivo

D. Yee, Hua Zhang, D. Sachdev, 2009, Clinical Cancer Research.

A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.

D. Yee, Shu-lian Li, Y. Fujita-Yamaguchi, 2003, Cancer research.

Abstract CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2014 .

Are the insulin-like growth factors relevant to cancer?

D. Yee, 2001, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Strain-specific differences in formation of apoptotic DNA ladders in MCF-7 breast cancer cells.

D. Yee, J. Gooch, 1999, Cancer letters.

Green Tea Catechin Extract Supplementation Does Not Influence Circulating Sex Hormones and Insulin-Like Growth Factor Axis Proteins in a Randomized Controlled Trial of Postmenopausal Women at High Risk of Breast Cancer.

D. Yee, Jian-Min Yuan, A. Wu, 2019, The Journal of nutrition.

Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.

D. Yee, R. Kratzke, B. Whitson, 2006, The Annals of thoracic surgery.

Generic entry of aromatase inhibitors and pharmaceutical access: Initiation of hormonal therapy, timeliness of initiation, and drug choice.

D. Yee, B. Virnig, P. Huckfeldt, 2020, Research in Social and Administrative Pharmacy.

Utilizing RNA-Seq to define phytochemical-induced alterations in insulin and IGF-regulated transcriptomes

D. Yee, H. Beckwith, 2014 .

Longitudinal assessment of bone loss from diagnostic computed tomography scans in gynecologic cancer patients treated with chemotherapy and radiation.

D. Yee, L. Downs, K. Dusenbery, 2010, American journal of obstetrics and gynecology.

Insulin-like growth factor-I and cancer risk.

D. Yee, Y. Ibrahim, 2004, Growth Hormone & IGF Research.

Progesterone Receptor-B Regulation of Insulin-Like Growth Factor–Stimulated Cell Migration in Breast Cancer Cells via Insulin Receptor Substrate-2

Adrian V. Lee, S. Byron, D. Yee, 2008, Molecular Cancer Research.

Case report: use of insulin-like growth factor-I gene expression to distinguish between breast and ovarian cancer.

D. Yee, P. Ravdin, J. Jackson, 1994, The American journal of the medical sciences.

The Influence of Therapeutic Radiation on the Patterns of Bone Remodeling in Ovary-Intact and Ovariectomized Mice

D. Yee, Manju Sharma, S. Hui, 2013, Calcified Tissue International.

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.

Rosalyn W. Sayaman, E. Petricoin, L. Esserman, 2022, Cancer cell.

Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.

L. Pusztai, D. Yee, C. Yau, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Type I Insulin-Like growth factor receptor

D. Yee, 2017 .

IGF 1 and IGF 2

D. Yee, 2017 .

Type I insulin-like growth factor receptor as a therapeutic target in cancer.

D. Yee, B. Miller, 2005, Cancer research.

Characterization of insulin-like growth factor binding proteins and regulation of IGFBP3 in human mesangial cells.

D. Yee, H. Abboud, S. Abboud, 1996, Kidney International.

Insulin-like growth factors, insulin, and growth hormone signaling in breast cancer: implications for targeted therapy.

D. Yee, H. Beckwith, 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Human Breast Cancer Insulin-like Growth Factor Receptor Expression and Function in Updated

W. Sly, D. Yee, N. Rosen, 2006 .

Insulin-like Growth Factor Receptor Expression and Function in Human Breast Cancer1

W. Sly, D. Yee, N. Rosen, 2006 .

Insulin-like Growth Factor Receptor Expression and Function in Human Breast

W. Sly, D. Yee, N. Rosen, 2006 .

The Role of p 21 in Interferon g-mediated Growth Inhibition of Human Breast Cancer Cells 1

D. Yee, R. Herrera, J. Gooch, 2000 .

The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells.

D. Yee, R. Herrera, J. Gooch, 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells.

D. Yee, J. Jackson, J. Figueroa, 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II).

N. Brünner, D. Yee, F. Kern, 1993, European journal of cancer.

The insulin-like growth factor system as a treatment target in breast cancer.

D. Yee, 2002, Seminars in oncology.

Targeting IGF-1R: at a crossroad.

Adrian V. Lee, D. Yee, A. Lee, 2011, Oncology.

Crosstalk Between IGF1R and Estrogen Receptor Signaling in Breast Cancer

D. Yee, Douglas Yee, Dedra H. Fagan, 2008, Journal of Mammary Gland Biology and Neoplasia.

Recombinant insulin‐like growth factor binding protein‐1 inhibits IGF‐I, serum, and estrogen‐dependent growth of MCF‐7 human breast cancer cells

S. Hilsenbeck, D. Yee, J. Jackson, 1993, Journal of cellular physiology.

Can the insulin-like growth factors regulate breast cancer growth?

D. Yee, 1992, Breast Cancer Research and Treatment.

Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features.

S. Hilsenbeck, D. Yee, J. Jackson, 1996, Journal of the National Cancer Institute.

Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice.

S. Hilsenbeck, C. Osborne, D. Yee, 1997, European journal of cancer.

Targeting IGF-1R: at a Crossroads

Adrian V. Lee, D. Yee, A. Lee, 2014 .

Is the Type I Insulin-Like Growth Factor Receptor a Therapeutic Target in Endometrial Cancer?

D. Yee, Hua Zhang, Hua Zhang, 2006, Clinical Cancer Research.

Insulinlike growth factors in human malignancy.

D. Yee, N. Rosen, K. Cullen, 1991, Cancer investigation.

A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells.

D. Yee, P. Rotwein, N. Brünner, 1990, Molecular endocrinology.

Prognostic indicators in early breast cancer.

W. McGuire, D. Yee, J. Figueroa, 1993, The American journal of the medical sciences.

Characterization of insulin‐like growth factor binding proteins (IGFBP) and regulation of IGFBP‐4 in bone marrow stromal cells

D. Yee, S. Abboud, P. Grellier, 1995, British journal of haematology.

Vascular Health and Risk Management Dovepress Utility of High-sensitivity Cardiac Troponin T in Patients Receiving Anthracycline Chemotherapy

D. Yee, D. Duprez, D. Vock, 2022 .

Characterization of Insulin‐Like Growth Factor‐I and Its Receptor and Binding Proteins in Transected Nerves and Cultured Schwann Cells

D. Yee, E. Feldman, G. Tennekoon, 1996, Journal of neurochemistry.

IGFs and IGFBPs in the Normal Mammary Gland and in Breast Cancer

D. Yee, T. Wood, 2004, Journal of mammary gland biology and neoplasia.

Water–fat MRI for assessing changes in bone marrow composition due to radiation and chemotherapy in gynecologic cancer patients

S. Moeller, D. Yee, L. Downs, 2013, Journal of magnetic resonance imaging : JMRI.

The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer.

D. Yee, N. Rosen, K. Cullen, 1991, Cancer treatment and research.

Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study

D. Yee, D. Duprez, N. Florea, 2017, Breast Cancer Research and Treatment.

Insulin-Like Growth Factor Binding Protein-1 Interacts With Integrins to Inhibit Insulin-Like Growth Factor-Induced Breast Cancer

D. Yee, J. Gross, 2002 .

A Tale of Two Receptors: Insulin and Insulin-Like Growth Factor Signaling in Cancer

D. Yee, 2014, Clinical Cancer Research.

The IGF Pathway Regulates ER (cid:1) through a S6K1-Dependent Mechanism in Breast Cancer Cells

D. Yee, X. Cui, Y. Ibrahim, 2011 .

Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3 9 -Kinase Inhibition

Adrian V. Lee, D. Yee, S. Oesterreich, 2000 .

Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice.

D. Yee, K. Kovacs, W. Ruan, 2007, Endocrinology.

Insulin-like Growth Factor Binding Protein-1 ( IGFBP-1 ) Inhibits Breast Cancer Cell Motility 1

D. Yee, Xihong Zhang, 2002 .

The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer

D. Yee, J. Figueroa, 1992, Breast Cancer Research and Treatment.

Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer.

S. Hilsenbeck, D. Yee, J. Sharma, 1994, Journal of the National Cancer Institute.

Gene expression of the insulin-like growth factors and their receptors in human neuroblastoma cell lines.

D. Yee, E. Feldman, R. Carlson, 1992, Brain research. Molecular brain research.

Gene expression of the insulin-like growth factors and their receptors in cultured human retinal pigment epithelial cells.

D. Yee, E. Feldman, D. M. Martin, 1992, Brain Research. Molecular Brain Research.

Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system

D. Yee, R. Kratzke, M. Kirstein, 2007, Cancer Chemotherapy and Pharmacology.

Review Imaging in breast cancer: Magnetic resonance spectroscopy

D. Yee, M. Nelson, M. Garwood, 2005 .

Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer

L. Esserman, D. Yee, A. DeMichele, 2017, The New England journal of medicine.

Combined Effects of Tamoxifen and a Chimeric Humanized Single Chain Antibody against the Type I IGF Receptor on Breast Tumor Growth In vivo

D. Yee, A. Wu, D. Ikle, 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action.

D. Yee, J. Jackson, D. Powell, 1992, Journal of the National Cancer Institute.

Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.

D. Yee, N. Rosen, D. Powell, 1990, The Journal of clinical investigation.

Use of dual-energy computed tomography to measure skeletal-wide marrow composition and cancellous bone mineral density

D. Yee, P. Bolan, S. Hui, 2017, Journal of Bone and Mineral Metabolism.

Receptor for Hyaluronan-Mediated Motility (RHAMM) defines an invasive niche associated with tumor progression and predicts poor outcomes in breast cancer patients

D. Yee, E. Turley, K. Cowan, 2022, bioRxiv.

Adaptor Proteins as Targets for Cancer Prevention

D. Yee, 2010, Cancer Prevention Research.

Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer.

S. McGuire, D. Yee, D. Allred, 1996, Human gene therapy.

Mutational impact of APOBEC3B and APOBEC3A in a human cell line

N. A. Temiz, M. Carpenter, D. Yee, 2022 .

40 YEARS OF IGF1: Anti-insulin-like growth factor therapy in breast cancer

D. Yee, 2018, Journal of Molecular Endocrinology.

Insulin‐like Growth Factor Binding Protein Expression in SH‐SY5Y Neuroblastoma Cells

D. Yee, E. Feldman, A. Randolph, 1993, Annals of the New York Academy of Sciences.

Insulin‐like Growth Factor Binding Protein Expression in Human Retinal Pigment Epithelial Cells

D. Yee, E. Feldman, A. Randolph, 1993, Annals of the New York Academy of Sciences.

DNA repair the 70-gene ultra-high risk as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

A. Glas, L. Esserman, T. Severson, 2017 .

The Influence of Therapeutic Radiation on the Patterns of Bone Marrow in Ovary-Intact and Ovariectomized Mice

D. Yee, S. Hui, Yan Zhang, 2012, PLoS ONE.

Longitudinal FDG-PET Revealed Regional Functional Heterogeneity of Bone Marrow, Site-Dependent Response to Treatment and Correlation with Hematological Parameters

D. Yee, S. Hui, J. Froelich, 2015, Journal of Cancer.

Role of Insulin-Like Growth Factor Receptors in Cancer Signaling

D. Yee, 2018, Predictive Biomarkers in Oncology.

Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.

S. Hilsenbeck, C. Osborne, D. Yee, 1999, Molecular endocrinology.

Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells

D. Yee, N. Zaveri, K. Gupta, 2006, Molecular Cancer Therapeutics.

How does the estrogen receptor work?

D. Yee, J. Gross, 2002, Breast Cancer Research.

Crosstalk Between the Insulin-Like Growth Factors and Estrogens in Breast Cancer

Adrian V. Lee, D. Yee, A. Lee, 2004, Journal of Mammary Gland Biology and Neoplasia.

Expression of Insulin-like Growth Factor I, Its Binding Proteins, and Its Receptor in Ovarian Cancer1

D. Yee, T. Hamilton, D. D. Hoff, 2006 .

The insulin-like growth factor system as a target in breast cancer

D. Yee, 2004, Breast Cancer Research and Treatment.

Regulation of human breast cancer by secreted growth factors.

D. Yee, S. Bates, N. Rosen, 1989, Acta oncologica.

Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues.

S. Hilsenbeck, S. McGuire, D. Yee, 1994, Cancer letters.

Insulin-like growth factors and breast cancer.

D. Yee, A. Lee, A. Lee, 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment

D. Yee, D. Duprez, D. Potter, 2015, SpringerPlus.

Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.

D. Yee, R. Kratzke, B. Whitson, 2006, The Annals of thoracic surgery.

Disrupting insulin-like growth factor signaling as a potential cancer therapy

D. Yee, D. Sachdev, 2007, Molecular Cancer Therapeutics.

Insulin‐like growth factor (IGF)‐I rescues breast cancer cells from chemotherapy‐induced cell death – proliferative and anti‐apoptotic effects

D. Yee, Douglas Yee, Jennifer L. Gooch, 1999, Breast Cancer Research and Treatment.

Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine

Richard C. Brundage, Amit Khatri, D. Yee, 2011, The AAPS Journal.

Acquired Tamoxifen Resistance in MCF-7 Breast Cancer Cells Requires Hyperactivation of eIF4F-Mediated Translation

D. Yee, M. Peterson, V. Polunovsky, 2017, Hormones and Cancer.

Coordinate alteration of pp60c-src abundance and c-src RNA expression in human neuroblastoma variants.

M. Israel, D. Yee, N. Rosen, 1989, Oncogene.

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.

D. Berry, L. Esserman, N. Hylton, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2.

Donald A. Berry, Nola M. Hylton, Rita Nanda, 2017 .

Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.

D. Yee, Jeffrey S. Miller, E. Chiorean, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The α2 and α3 integrins are required for morphologic differentiation of an intestinal epithelial cell line

D. Yee, J. Garcia-Aguilar, Xihong Zhang, 2003 .

Disrupting Insulin and IGF Receptor Function in Cancer

D. Yee, Jingran Cao, 2021, International journal of molecular sciences.

Inducible expression of herpes simplex virus thymidine kinase increases sensitivity to ganciclovir but does not enhance bystander effect in breast cancer cells

D. Yee, J. Chavez, R. Patil, 2000, Breast Cancer Research and Treatment.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

D. Berry, E. Petricoin, A. Glas, 2017, npj Breast Cancer.

Forkhead Homologue in Rhabdomyosarcoma Functions as a Bifunctional Nuclear Receptor-interacting Protein with Both Coactivator and Corepressor Functions*

C. Osborne, S. Fuqua, P. Brown, 2001, The Journal of Biological Chemistry.

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.

D. Yee, J. Engelman, C. Arteaga, 2008, The Journal of clinical investigation.

Recent advances in neoadjuvant therapy for breast cancer

D. Yee, D. Potter, Michael J Franklin, 2021, Faculty Reviews.

Insulin-Like Growth Factor I-Induced Degradation of Insulin Receptor Substrate 1 Is Mediated by the 26S Proteasome and Blocked by Phosphatidylinositol 3′-Kinase Inhibition

Adrian V. Lee, D. Yee, S. Oesterreich, 2000, Molecular and Cellular Biology.

Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells*

D. Yee, M. White, J. Jackson, 1998, The Journal of Biological Chemistry.

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.

D. Berry, L. Esserman, N. Hylton, 2021, Cancer cell.

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.

D. Berry, L. Esserman, N. Hylton, 2020, JAMA oncology.

Inhibition of Cancer Cell Proliferation and Metastasis by Insulin Receptor Downregulation

D. Yee, Hua Zhang, D. Sachdev, 2010, Oncogene.

The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer

Reuben S Harris, Rachel Isaksson Vogel, John W M Martens, 2016, Science Advances.

Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.

D. Berry, L. Esserman, N. Hylton, 2015 .

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Anne M Wallace, Michael Hogarth, Lajos Pusztai, 2016, The New England journal of medicine.

MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer

D. Yee, D. Cittelly, A. Elias, 2010, Hormones & cancer.

Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer

D. Yee, Shilpa Gupta, 2016 .

The type I insulin-like growth factor receptor regulates cancer metastasis independently of primary tumor growth by promoting invasion and survival

D. Yee, D. Sachdev, M. Gaillard-Kelly, 2009, Oncogene.

A Dominant Negative Type I Insulin-like Growth Factor Receptor Inhibits Metastasis of Human Cancer Cells*

Adrian V. Lee, D. Yee, D. Sachdev, 2004, Journal of Biological Chemistry.

Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment

T. Niu, D. Yee, J. Jackson, 2018, Breast Cancer Research.

Crosstalk Between Estrogen Receptors and Growth Factor Signaling

D. Yee, C. Lange, 2002 .

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

E. Petricoin, L. Esserman, N. Hylton, 2022, npj Breast Cancer.

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

D. Berry, E. Petricoin, L. Esserman, 2021, NPJ breast cancer.

I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer

D. Yee, Haiyun Wang, 2019, Current Breast Cancer Reports.

Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL.

D. Berry, E. Petricoin, L. Esserman, 2018, JCO precision oncology.

532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial

D. Berry, A. Glas, N. Hylton, 2014 .

Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes

D. Yee, Yan Peng, G. Raj, 2014, Oncogene.

Abstract 3572: Unliganded progesterone receptors augment estrogen-induced growth of breast cancer cells via co-regulation of estrogen receptor target genes.

D. Yee, J. Ostrander, C. Lange, 2013 .

Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.

D. Yee, D. Sachdev, D. Fagan, 2012, Cancer research.

Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop.

D. Yee, J. Jackson, J. Figueroa, 1995, The Journal of clinical endocrinology and metabolism.

The insulin-like growth factor family of ligands, receptors, and binding proteins

D. Yee, R. Krywicki, 1992, Breast Cancer Research and Treatment.

Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer.

D. Yee, N. Rosen, M. Lippman, 1989, Molecular endocrinology.

The insulin-like growth factor binding protein BP-25 is expressed by human breast cancer cells.

D. Yee, R. Lupu, R. Dickson, 1989, Biochemical and biophysical research communications.

Igf system components as prognostic markers in breast cancer

Adrian V. Lee, S. Hilsenbeck, D. Yee, 1998, Breast Cancer Research and Treatment.

Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.

D. Yee, J. Gooch, Adrian V. Lee, 1998, Cancer Research.

Expression of insulin‐like growth factor binding proteins in human breast cancer correlates with estrogen receptor status

W. McGuire, D. Yee, J. Jackson, 1993, Journal of cellular biochemistry.

Insulin-like growth factor receptor expression and function in human breast cancer.

W. Sly, D. Yee, N. Rosen, 1990, Cancer research.

Insulin-like growth factor II mRNA expression in human breast cancer.

D. Yee, N. Rosen, M. Lippman, 1988, Cancer research.

eIF4E threshold levels differ in governing normal and neoplastic expansion of mammary stem and luminal progenitor cells.

D. Yee, M. Peterson, V. Polunovsky, 2015, Cancer Research.

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells.

N. Sonenberg, D. Yee, M. Peterson, 2004, Cancer cell.

EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.

D. Yee, D. Leroith, D. Sachdev, 2016, Endocrine-related cancer.

Of mice and (wo)men: is this any way to test a new drug?

D. Yee, T. Haddad, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New Mechanisms of Signal Transduction Inhibitor Action

Steffi Oesterreich, Adrian V. Lee, Rachel Schiff, 2003 .

New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.

Steffi Oesterreich, Adrian V. Lee, Adrian V Lee, 2003, Clinical Cancer Research.

IGF-I regulates redox status in breast cancer cells by activating the amino acid transport molecule xC-.

D. Yee, Yu-zhi Yang, 2014, Cancer Research.

Revisiting the IGF-1R as a breast cancer target

D. Yee, Douglas Yee, Roudy Chiminch Ekyalongo, 2017, npj Precision Oncology.

Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer

D. Yee, Yu-zhi Yang, 2012, Journal of Mammary Gland Biology and Neoplasia.

Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth.

D. Yee, P. Law, R. Hebbel, 2002, Cancer research.

Crosstalk Between Insulin-like Growth Factor (IGF) and Epidermal Growth Factor (EGF) Receptors

D. Yee, M. Becker, 2008 .

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.

N. Hylton, L. Pusztai, D. Yee, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

CCR 20th Anniversary Commentary: Stayin' Alive—Antiapoptotic Proteins and Breast Cancer

D. Yee, 2015, Clinical Cancer Research.

Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives.

D. Yee, Chun Wang, Hua Zhang, 2008, Nanomedicine.

The IGF system and breast cancer.

D. Yee, D. Sachdev, M. Becker, 2001, Endocrine-related cancer.

In vivo quantification of choline compounds in the breast with 1H MR spectroscopy

Michael Garwood, Patrick J Bolan, D. Yee, 2003, Magnetic resonance in medicine.

DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 4-aminobiphenyl are infrequently detected in human mammary tissue by liquid chromatography/tandem mass spectrometry.

D. Yee, Jian-Min Yuan, S. Langouët, 2012, Carcinogenesis.

The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: Biology and therapeutic relevance

D. Yee, J. Gross, 2003, Cancer and Metastasis Reviews.

Multiple Signaling Pathways are Activated During Insulin-like Growth Factor-I (IGF-I) Stimulated Breast Cancer Cell Migration

D. Yee, K. Itoh, K. Golen, 2005, Breast Cancer Research and Treatment.

Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells

S. Byron, D. Yee, C. Lange, 2006, British Journal of Cancer.

Insulin-like growth factor receptor inhibitors: baby or the bathwater?

D. Yee, 2012, Journal of the National Cancer Institute.

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

L. Esserman, W. Fraser Symmans, D. Yee, 2018, npj Breast Cancer.

Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility.

D. Yee, Xihong Zhang, 2002, Cancer research.

Cyclin E in breast cancer.

D. Yee, 2003, The New England journal of medicine.

D. Yee, Aleksandra M. Ochnik, 2012, Breast Cancer Research.

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

D. Berry, E. Petricoin, L. Esserman, 2021, Nature Communications.

Mutational impact of APOBEC3B and APOBEC3A in a human cell line

M. Carpenter, D. Yee, W. Brown, 2022 .

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

D. Berry, L. Esserman, N. Hylton, 2020, JAMA oncology.

Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells

D. Yee, Xihong Zhang, Michael R. Diaz, 2013, Breast Cancer Research and Treatment.

Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor

D. Yee, Hua Zhang, A. Oh, 2012, Breast Cancer Research and Treatment.

Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells

D. Yee, Andrew Skildum, D. Fagan, 2015, SpringerPlus.

Targeting the insulin-like growth factor axis as a cancer therapy.

D. Yee, T. Haddad, 2006, Future oncology.

The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics

D. Yee, Jian-Min Yuan, A. Wu, 2015, Cancer Causes & Control.

A Randomized Controlled Trial of Green Tea Extract Supplementation and Mammographic Density in Postmenopausal Women at Increased Risk of Breast Cancer

D. Yee, Jian-Min Yuan, A. Wu, 2017, Cancer Prevention Research.

Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer.

H. Rui, D. Yee, K. Wisinski, 2021, Endocrinology.

STAT6 mediates interleukin-4 growth inhibition in human breast cancer cells.

D. Yee, B. Christy, Douglas Yee, 2002, Neoplasia.

Elevated levels of p66 Shc are found in breast cancer cell lines and primary tumors with high metastatic potential.

D. Yee, G. Clark, J. Jackson, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer.

R. Weber, S. Lippman, W. Hong, 1993, Investigational new drugs.

Insulin-like growth factor-I and breast cancer therapy.

D. Yee, Y. Ibrahim, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Selective Activation of Insulin Receptor Substrate-1 and -2 in Pleural Mesothelioma Cells

Chuong D. Hoang, D. Yee, C. Hoang, 2004, Cancer Research.

IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas

D. Yee, D. Sachdev, M. Cairo, 2015, PloS one.

Targeting insulin-like growth factor pathways.

D. Yee, D Yee, 2007, British journal of cancer.

An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer

D. Yee, T. Haddad, Kalpna Gupta, 2022, Investigational New Drugs.

Cloning, Chromosome Localization, Expression, and Characterization of an Src Homology 2 and Pleckstrin Homology Domain-containing Insulin Receptor Binding Protein hGrb10γ*

Adrian V. Lee, L. F. Kolakowski, D. Yee, 1997, Journal of Biological Chemistry.

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.

D. Berry, L. Esserman, N. Hylton, 2021, JAMA oncology.

Skeletal Remodeling Following Clinically Relevant Radiation-Induced Bone Damage Treated with Zoledronic Acid

D. Yee, Manju Sharma, S. Hui, 2011, Calcified Tissue International.

The therapeutic potential of agents targeting the type I insulin-like growth factor receptor

D. Yee, Hua Zhang, Hua Zhang, 2004, Expert opinion on investigational drugs.

Motility Response to Insulin-like Growth Factor-I (IGF-I) in MCF-7 Cells is Associated with IRS-2 Activation and Integrin Expression

D. Yee, F. Hakuno, Shin-ichiro Takahashi, 2004, Breast Cancer Research and Treatment.

Regulation of breast cancer cell motility by insulin receptor substrate-2 (IRS-2) in metastatic variants of human breast cancer cell lines

D. Yee, T. Yoneda, J. Jackson, 2001, Oncogene.

Identification of insulin-like growth factor binding proteins in breast cancer cells

D. Yee, D. Powell, M. Lippman, 1991, Breast Cancer Research and Treatment.

40 YEARS OF IGF1: Anti-insulin-like growth factor therapy in breast cancer

D. Yee, 2018, Journal of Molecular Endocrinology.

The emerging role of the fetal insulin receptor (IR-A) in hormone-refractory breast cancer.

D. Yee, Tanvi Mathur, 2021, Endocrinology.

YEARS OF IGF 1 Anti-insulin-like growth factor therapy in breast cancer

D. Yee, 2018 .

Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.

D. Yee, D. Kiang, Hua Zhang, 2007, Cancer research.

Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival.

S. Hilsenbeck, D. Yee, S. Hilsenbeck, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Randomized controlled trial of weight training and lymphedema in breast cancer survivors.

D. Yee, R. Ahmed, W. Thomas, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The IGF pathway regulates ERα through a S6K1-dependent mechanism in breast cancer cells.

Adrian V. Lee, D. Yee, X. Cui, 2011, Molecular Endocrinology.

APOBEC3B is an enzymatic source of mutation in breast cancer

Jason B. Nikas, Lela Lackey, M. Carpenter, 2013, Nature.

Should diabetic women with breast cancer have their own intervention studies?

D. Yee, D. Potter, Zhijun Guo, 2012, Endocrine-Related Cancer.

Disruption of insulin receptor function inhibits proliferation in endocrine resistant breast cancer cells

D. Yee, K. LaPara, J. Y. Chan, 2015, Oncogene.

Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer.

Sara A Byron, S. Byron, D. Yee, 2003, Seminars in oncology.

Effects of weight training on quality of life in recent breast cancer survivors

D. Yee, K. Schmitz, R. Ahmed, 2006, Cancer.

The Influence of Therapeutic Radiation on the Patterns of Bone Remodeling in Ovary-Intact and Ovariectomized Mice

D. Yee, Manju Sharma, S. Hui, 2013, Calcified Tissue International.

Abstract PD6-14: Analysis of DNA repair deficiency biomarkers as predictors of response to the PD1 inhibitor pembrolizumab: Results from the neoadjuvant I-SPY 2 trial for stage II-III high-risk breast cancer

D. Yee, C. Yau, A. Sanil, 2018 .

Consensus Reports

Lee C. Rogers, William H. Herman, Kirkman, 2011, Diabetes Care.

Omission of radiation therapy after breast‐conserving surgery in the United States

D. Yee, Jianlin Yuan, T. Tuttle, 2012, Cancer.

Effects of a 9-month strength training intervention on insulin, insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-1, and IGFBP-3 in 30-50-year-old women.

D. Yee, K. Schmitz, R. Ahmed, 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

D. Yee, S. Bruno, A. Decensi, 1998, British Journal of Cancer.

Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells.

D. Yee, J. Jackson, C. Weng, 1997, The Journal of endocrinology.

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

L. Esserman, L. Pusztai, D. Yee, 2022, Journal of Clinical Oncology.

Impact of body mass index on pathological complete response following neoadjuvant chemotherapy in operable breast cancer: a meta-analysis

D. Yee, D. Potter, S. Basu, 2021, Breast Cancer.

Inhibitors of Insulin-like Growth Factor Signaling: A Therapeutic Approach for Breast Cancer

D. Yee, D. Sachdev, 2006, Journal of Mammary Gland Biology and Neoplasia.

Commentary: Killing The Second Messenger: Targeting Loss of Cell Cycle Control in Endocrine Resistant Breast Cancer Running Title: Targeting Cell Cycle Control in Breast Cancer

D. Yee, C. Lange, 2011 .

Eliminating spurious lipid sidebands in 1H MRS of breast lesions

Hellmut Merkle, Michael Garwood, Lance DelaBarre, 2002, Magnetic resonance in medicine.

Imaging in breast cancer: Magnetic resonance spectroscopy

Michael Garwood, Patrick J Bolan, M. Garwood, 2005, Breast Cancer Research.

Transforming the clinical trial process: The I-SPY 2 trial as a model for improving the efficiency of clinical trials and accelerating the drug-screening process.

D. Berry, L. Esserman, N. Hylton, 2014 .

Mobile Phone Multilevel and Multimedia Messaging Intervention for Breast Cancer Screening: Pilot Randomized Controlled Trial

D. Yee, Anna Leinonen, Monica Sharratt, 2017, JMIR mHealth and uHealth.

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

L. Esserman, M. Troxell, D. Yee, 2018 .

Insulin-like growth factor II mRNA expression in human breast cancer.

D. Yee, N. Rosen, M. Lippman, 1988, Cancer research.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Anne Wallace, Emanuel F Petricoin, Rita Nanda, 2015, Clinical Cancer Research.

Spatial and Temporal Fracture Pattern in Breast and Gynecologic Cancer Survivors

D. Yee, S. Hui, R. Shanley, 2015, Journal of Cancer.

Validation of marrow fat assessment using noninvasive imaging with histologic examination of human bone samples.

D. Yee, P. Bolan, S. Hui, 2015, Bone.

Exogenous near-infrared fluorophores and their applications in cancer diagnosis: biological and clinical perspectives.

D. Yee, Hua Zhang, Douglas Yee, 2011, Expert opinion on medical diagnostics.

Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer

Adrian V. Lee, C. Fan, C. Perou, 2016, PloS one.

Pharmacokinetic profile of recombination human insulin-like growth factor binding protein-1 in athymic mice.

D. Yee, G. N. Cox, J. Kuhn, 1996, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Abstract PD9-02: Personalized ctDNA as a predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without pembrolizumab (P)

L. Esserman, S. Shchegrova, Hsin-Ta Wu, 2021 .

Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL

L. Esserman, S. Vandenberg, Minetta C. Liu, 2019, Clinical Trials.

Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies

S. Loi, D. Yee, C. Yau, 2019, Poster Session Abstracts.

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.

Rosalyn W. Sayaman, L. Esserman, N. Hylton, 2023, Cancer cell.

Targeting insulin-like growth factor pathways

D. Yee, D Yee, 2006, British Journal of Cancer.

Abstract 2679: Integration of DNA repair deficiency and immune biomarkers to predict which early-stage triple-negative breast cancer patients are likely to respond to platinum-containing regimens vs. immunotherapy: The neoadjuvant I-SPY 2 trial

E. Petricoin, L. Esserman, O. Olopade, 2019, Clinical research.

Growth Regulation of Human Breast Cancer by Insulin-Like Growth Factors

D. Yee, N. Rosen, M. Lippman, 1989 .

Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore

D. Yee, C. Wagner, H. Zhang, 2009, British Journal of Cancer.

64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.

D. Yee, B. Hackel, Brett A. Case, 2016, Molecular Pharmaceutics.

IGF-1 Stimulates Glycolytic ATP Production in MCF-7L Cells

D. Yee, Xihong Zhang, Bhumika Rajoria, 2023, International journal of molecular sciences.

Introduction: IGFs and IGFBPs in the normal mammary gland and in breast cancer.

D. Yee, T. Wood, 2000, Journal of mammary gland biology and neoplasia.

Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

D. Berry, N. Hylton, D. Yee, 2017 .

Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial

D. Berry, N. Hylton, D. Yee, 2017 .

Abstract P1-14-03: The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL

N. Hylton, D. Yee, C. Yau, 2016 .

Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time

D. Yee, N. Florea, D. Potter, 2023, Research square.

D. Yee, Jian-Min Yuan, A. Wu, 2015, Cancer Causes and Control.

A phase I feasibility study of multi-modality imaging assessing rapid expansion of marrow fat and decreased bone mineral density in cancer patients.

D. Yee, L. Downs, B. Zobel, 2015, Bone.

Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2020 .

Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2020 .

Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells

D. Yee, Yu-zhi Yang, N. Temiz, 2018, Hormones and Cancer.

Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T.

K. Brandt, C. Le, D. Yee, 2005, Radiology.

Targeting the insulin-like growth factor receptor.

D. Yee, 2009, Clinical advances in hematology & oncology : H&O.

Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial

D. Yee, C. Yau, P. Pohlmann, 2023, Research square.

Abstract CT106: Efficacy of pertuzumab/trastuzumab/paclitaxel over standard trastuzumab/paclitaxel therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2016 .

Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2016 .

Faculty Opinions recommendation of Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

D. Yee, 2009 .

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

Sourav Bandyopadhyay, L. Esserman, M. Sirota, 2023, bioRxiv.

Therapeutics , Targets , and Chemical Biology AcquiredResistance to Tamoxifen Is Associatedwith Loss of the Type I Insulin-like Growth Factor Receptor : Implications for Breast Cancer Treatment

D. Yee, D. Sachdev, D. Fagan, 2012 .

Therapeutics , Targets , and Chemical Biology Acquired Resistance to Tamoxifen Is Associatedwith Loss of the Type I Insulin-like Growth Factor Receptor : Implications for Breast Cancer Treatment

D. Yee, D. Sachdev, D. Fagan, 2012 .

Lac repressor inducible gene expression in human breast cancer cells in vitro and in a xenograft tumor.

S. McGuire, D. Yee, D. Wolf, 1997, BioTechniques.

D. Yee, M. Koizumi, K. Ogawa, 2014, Calcified Tissue International.

Yin Yang Gene Expression Ratio Signature for Lung Cancer Prognosis

D. Yee, S. Banerji, R. Kratzke, 2013, PloS one.

Locally advanced prostate cancer: A population-based study of treatment patterns and predictors.

W. Lowrance, E. Elkin, L. Jacks, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

I. L. Fernandes, L. Esserman, D. Yee, 2019, npj Breast Cancer.

Abstract CT136: Evaluation of talazoparib in combination with irinotecan in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL

L. Esserman, N. Hylton, D. Yee, 2019, Clinical Trials.

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials

D. Berry, L. Esserman, O. Olopade, 2013, Clinical Cancer Research.

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

David Wholley, Anne Wallace, Michael Hogarth, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S4-07: Tamoxifen resistance driven by the DNA cytosine deaminase APOBEC3B in recurrent estrogen receptor positive breast cancer

J. Foekens, J. Martens, P. Span, 2016 .

Growth regulation of breast cancer.

D. Yee, M. Lippman, 1989, Progress in clinical and biological research.

Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL

D. Berry, L. Esserman, N. Hylton, 2021 .

Basic Principles of Antineoplastic Therapies

D. Yee, T. Haddad, 2010 .

Mutational impact of APOBEC 3 A and APOBEC 3 B in a human cell line 1 and comparisons to breast cancer 2 3 Running title : Mutation signatures of APOBEC 3 A and APOBEC 3 B 4 5 6

M. Carpenter, D. Yee, W. Brown, 2023 .

How to Train Your Biomarker

D. Yee, 2010, Clinical Cancer Research.

Case report: use of insulin-like growth factor-I gene expression to distinguish between breast and ovarian cancer.

D. Yee, D. V. Von Hoff, P. Ravdin, 1994, The American journal of the medical sciences.

40 YEARS OF IGF1: Anti-insulin-like growth factor therapy in breast cancer

D. Yee, 2018, Journal of Molecular Endocrinology.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial

D. Berry, E. Petricoin, A. Glas, 2017, npj Breast Cancer.

P1-17-01: Figitumumab Plus Exemestane Versus Exemestane as First-Line Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer: A Randomized, Open-Label Phase II Trial.

P. Neven, D. Yee, K. Blackwell, 2011 .

Insulin-like growth factor binding proteins: Potential inhibitors of cancer cell growth

D. Yee, J. Figueroa, 1994 .

Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.

G. Colditz, P. Lønning, C. Osborne, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine

D. Yee, M. Kirstein, R. Brundage, 2012, The AAPS Journal.

Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer

D. Yee, Xihong Zhang, 2000, Breast Cancer Research.

How to Train Your Biomarker

D. Yee, 2010, Clinical Cancer Research.

Disrupting insulin-like growth factor signaling as a potential cancer therapy

D. Yee, D. Sachdev, 2007, Molecular Cancer Therapeutics.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

L. Esserman, N. Hylton, O. Olopade, 2016, The New England journal of medicine.

Title: the Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer Statement of Translational Relevance

Parker, D. Berry, E. Petricoin, 2015 .

Inhibition of Cancer Cell Proliferation and Metastasis by Insulin Receptor Downregulation

D. Yee, Hua Zhang, D. Sachdev, 2010, Oncogene.

EMT reversal in human cancer cells after IR knockdown in hyperinsulinemic mice.

D. Yee, D. Leroith, D. Sachdev, 2016, Endocrine-related cancer.

Diabetes and Cancer

D. Yee, E. Giovannucci, S. Gapstur, 2010, Diabetes Care.

Endothelial dysfunction in breast cancer survivors on aromatase inhibitors: changes over time

D. Yee, D. Potter, R. Vogel, 2024, Cardio-oncology.

Abstract P2-11-02: A longitudinal look at toxicity management within a platform trial: Lessons from the I-SPY 2 TRIAL

D. Berry, D. Yee, M. Paoloni, 2017 .

The IGF Pathway Regulates ER-α through A S6K1-Dependent Mechanism in Breast Cancer Cells

Adrian V. Lee, D. Yee, X. Cui, 2011 .

- Activating the Amino Acid Transport Molecule xC IGF-I Regulates Redox Status in Breast Cancer Cells by

D. Yee, Yu-zhi Yang, 2014 .

Skeletal Remodeling Following Clinically Relevant Radiation-Induced Bone Damage Treated with Zoledronic Acid

D. Yee, Manju Sharma, S. Hui, 2011, Calcified Tissue International.

Arterial elasticity in testicular cancer survivors.

D. Yee, D. Duprez, D. Mulrooney, 2014 .

The IGF System in Mammary Development and Breast Cancer

D. Yee, T. Wood, 2008, Journal of Mammary Gland Biology and Neoplasia.

Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).

A. Glas, L. Esserman, L. Pusztai, 2023, Journal of Clinical Oncology.

The type I IGF receptor as a target for breast cancer therapy.

D. Yee, Xihong Zhang, 2003, Breast disease.

STRENGTH TRAINING AND LYMPHEDEMA SYMPTOMS IN RECENT BREAST CANCER SURVIVORS

D. Yee, K. Schmitz, R. Ahmed, 2003 .

MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial

Elizabeth A Morris, Constantine A Gatsonis, Michael Garwood, 2017, Journal of magnetic resonance imaging : JMRI.

Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system.

C. Le, D. Yee, R. Kratzke, 2007, Lung cancer.